Compare Neurocrine Biosciences Inc (NBIX) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Newmont Corporation — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Newmont Corporation trades at $117.84 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 8.5× Neurocrine Biosciences Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Newmont Corporation for 58 Days on average.
| NBIX | NEM | |
|---|---|---|
Market Cap | $14.36B | $121.75B |
Volume | 1,237,180 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $135.14 |
52-Week Low | $123.10 | $78.63 |
Typical Hold Time | 23 Days | 58 Days |
Enterprise Value | $14.37B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
Newmont Corporation (NEM) trades at $115.55, up 1.77% today, with a bearish technical signal despite strong fundamentals. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025, with net income margin expanding to 33.36%.
Outlook remains positive with a consensus price target of $136.83, implying 18% upside, supported by operational improvements and favorable gold prices. Risks include gold price volatility and execution of growth projects. Analyst sentiment is strongly bullish with 76% buy ratings and no sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
